Vlad Slepnev

Vlad Slepnev is the Chief Scientific Advisor at Curative. Vlad has also served as the CSO at Curative-Korva from March 2020 to February 2022, and as the VP of Research and Development at Shield Bio from October 2018 to January 2020.

Slepnev began their career at Meridian Bioscience in January 2010, where they served as the Sr. Director of Technology Development, Research, and Product Development. In this role, they led the product development arm of R&D, creating a menu of molecular diagnostic products on a new isothermal diagnostic platform (illumigene). Within seven years, they had developed nine 510K-cleared and eleven CE-marked molecular tests.

Some of their notable accomplishments include developing the first amplified molecular Group A assay to receive 510K-clearance, as well as the first 510K-cleared assays for detection of Mycoplasma pneumoniae and Bordetella pertussis. Vlad also developed the first de novo 510-cleared test for congenital CMV, and the first field-deployable molecular diagnostic test for detection of malaria endorsed by CDC.

In addition to their work in product development, Slepnev has also participated in identifying product opportunities, conducting market research, designing assays, optimizing processes, and evaluating clinical performance in pre-submission studies. Vlad has also assisted in the preparation of 8 FDA 510K submissions and pre-IDE communication for multiple diagnostic products.

Slepnev has also been responsible for recruiting scientific advisors and clinical consultants, setting up invited speaker programs including leading clinical directors and key opinion leaders in molecular diagnostics of infectious diseases. Vlad has coauthored more than 20 poster presentations at Clinical Virology Symposium, AMP, ASM and ECCMID conferences.

In their most recent role as Chief Science Officer at Curative, Slepnev is continuing their work in developing innovative diagnostic solutions to improve patient care.

Vlad Slepnev's educational career includes a postdoctoral fellowship in cell/molecular biology at Yale University School of Medicine, followed by another postdoctoral fellowship in the same field at the institute Pasteur in Paris, France. Vlad also has a degree in chemistry from Lomonosov Moscow State University (MSU) and a degree in managing healthcare delivery from Harvard Business School.